


## PHARMACEUTICAL 2021



## Spero Therapeutics Inc. Rank 130 of 402





## PHARMACEUTICAL 2021



## Spero Therapeutics Inc. Rank 130 of 402

The relative strengths and weaknesses of Spero Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Spero Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 55% points. The greatest weakness of Spero Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 170%, being 123% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	139,145
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,343
Liabilities, Non-Current	6,891
Other Assets	12,637
Other Compr. Net Income	-23
Other Expenses	0
Other Liabilities	177
Other Net Income	833
Other Revenues	9,330
Property and Equipment	1,669
Research and Development	67,003
Selling, General and Administrative Expense	21,440

Output Variable	Value in 1000 USD
Assets	153,451
Liabilities	21,411
Expenses	88,443
Revenues	9,330
Stockholders Equity	132,040
Net Income	-78,280
Comprehensive Net Income	-78,292
Economic Capital Ratio	170%

